Actionable news
0
All posts from Actionable news
Actionable news in STML: Stemline Therapeutics, Inc.,

Stemline Therapeutics Announces Oral Presentation of SL-401 Phase 2 BPDCN Data at the 2016 ASCO Annual Meeting

NEW YORK, Apr 25, 2016 (GLOBE NEWSWIRE via COMTEX) --

Stemline Therapeutics, Inc. STML, +1.40% announced today that its SL-401 Phase 2 clinical data update was selected for oral presentation on June 4, 2016 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Details on the presentation are as follows:

Title:
Results from Phase 2 registration trial of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lead-in completed, Expansion stage ongoing.
Presenter: Naveen Pemmaraju, M.D., MD Anderson Cancer Center
Abstract No.: 7006
Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date/Time: Saturday, June 4, 2016; 5:00 - 5:12PM CT
Location: Arie Crown Theater

Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "We are honored that ASCO has selected our Phase 2 data update for an oral presentation at this year's annual meeting. We are also privileged to be working with world-class collaborators and institutions on this important trial and look forward to Dr. Pemmaraju's presentation and data updates at the meeting."

About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage...


More